Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

During the SELECT trial, almost 30 percent of individuals stopped using semaglutide, but "real-world estimates" of GLP-1 RA ...